Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma
| Autor: | Robert E. Bellet, David Berd, Robert B. Catalano, Michael J. Mastrangelo |
|---|---|
| Rok vydání: | 1978 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Nitrosourea Vomiting Injections Subcutaneous medicine.medical_treatment Drug Resistance Phases of clinical research Drug resistance chemistry.chemical_compound Refractory Bone Marrow Internal medicine Humans Medicine Neoplasm Metastasis Melanoma Chemotherapy business.industry medicine.disease Dacarbazine Metastatic malignant melanoma chemistry Pediatrics Perinatology and Child Health Toxicity Azacitidine Drug Evaluation Female business |
| Zdroj: | Medical and Pediatric Oncology. 4:11-15 |
| ISSN: | 1096-911X 0098-1532 |
| DOI: | 10.1002/mpo.2950040104 |
| Popis: | Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC-45388) and a nitrosourea were treated with 5-azacytidine (NSC-102816). 5-Azacytidine was administered subcutaneously at a dosage of 100 mg/m2/day for 10 days. Twenty-six (26) patients were evaluable for toxicity and response. Major organ toxicities were hematologic, gastrointestinal, and cutaneous; no antitumor activity was noted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text